Mohamed Eltahir

An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Eltahir, Mohamed; Lauren, Ida; Lord, Martin; Chourlia, Aikaterini et al.

Part of Advanced Therapeutics, 2022

• DOI for An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
• Download full text (pdf) of An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

Lauren, Ida; Havervall, Sebastian; Ng, Henry; Lord, Martin et al.

Part of Immunity, Inflammation and Disease, 2022

• DOI for Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology
• Download full text (pdf) of Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Eltahir, Mohamed; Isaksson, Johan; Mattsson, Johanna Sofia Margareta; Karre, Klas et al.

Part of Cancers, 2021

• DOI for Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
• Download full text (pdf) of Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer

Backman, Max; La Fleur, Linnea; Kurppa, Pinja; Djureinovic, Dijana et al.

Part of Journal of Pathology, p. 243-256, 2021

• DOI for Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer
• Download full text (pdf) of Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Eltahir, mohmo394; Fletcher, E.; Dynesius, L.; Jarblad, J. L. et al.

Part of International Immunopharmacology, 2021

• DOI for Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients
• Download full text (pdf) of Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Eltahir, Mohamed; Lauren, Ida; Lord, Martin; Chourlia, Aikaterini et al.

Part of Advanced Therapeutics, 2022

• DOI for An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
• Download full text (pdf) of An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

Lauren, Ida; Havervall, Sebastian; Ng, Henry; Lord, Martin et al.

Part of Immunity, Inflammation and Disease, 2022

• DOI for Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology
• Download full text (pdf) of Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Eltahir, Mohamed; Isaksson, Johan; Mattsson, Johanna Sofia Margareta; Karre, Klas et al.

Part of Cancers, 2021

• DOI for Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
• Download full text (pdf) of Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer

Backman, Max; La Fleur, Linnea; Kurppa, Pinja; Djureinovic, Dijana et al.

Part of Journal of Pathology, p. 243-256, 2021

• DOI for Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer
• Download full text (pdf) of Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Eltahir, mohmo394; Fletcher, E.; Dynesius, L.; Jarblad, J. L. et al.

Part of International Immunopharmacology, 2021

• DOI for Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients
• Download full text (pdf) of Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Flodvåg av långtidssjuka covid-19-patienter väntar

Rostedt Punga, Anna; Strømme, Maria; Alimohammadi, Mohammad; Eltahir, Mohamed et al.

Part of Dagens Nyheter, p. 5-5, 2020

Tumor localized agonistic anti-CD40 therapy and beyond

Eltahir, Mohamed; Persson, Helena; Mangsbo, Sara

Part of Expert Opinion on Biological Therapy, p. 215-217, 2020

• DOI for Tumor localized agonistic anti-CD40 therapy and beyond

Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics

Fletcher, Erika A. K.; Eltahir, Mohamed; Lindqvist, Frida; Rieth, Jonas et al.

Part of International Immunopharmacology, p. 1-11, 2018

• DOI for Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics
• Download full text (pdf) of Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics

Antibody-based Cancer Immunotherapy: Personalization, response prediction and safety considerations

Eltahir, Mohamed

2021

• Download full text (pdf) of Antibody-based Cancer Immunotherapy: Personalization, response prediction and safety considerations

Extending the immune phenotypes of lung cancer: Oasis in the desert

Backman, Max; La Fleur, Linnea; Kurppa, Pinja; Djureinovic, Dijana et al.

An adaptable antibody-based platform for flexible synthetic peptide-based cargo delivery based on agonistic CD40-directed antibodies

Eltahir, Mohamed; Lauren, Ida; Lord, Martin; Chourlia, Aikaterini et al.

Plasma proteomic analysis in non-small cell lung cancer patients treated with PD1/PD-L1 blockade

Eltahir, Mohamed; Isaksson, Johan; Mattsson, Johanna Sofia Margareta; Kärre, Klas et al.